Sam Brusco, Associate Editor06.08.22
Medtronic has appointed Dr. Ashwini (Ash) Sharan as the chief medical officer of its Neuromodulation business.
Dr. Sharan is one of the top neurosurgeons in the U.S. with 25 years of experience. He is currently co-director of the Neuro Restoration Center and Professor of Neurological Surgery and Neurology at Thomas Jefferson University, Jefferson Medical College, and previously held roles of President for both the Congress of Neurological Surgeons and the North American Neuromodulation Society.
Dr. Sharan will shape the company’s strategic direction of innovation and clinical evidence plans, guide physician, society, and education engagements, serve as the business’s medical advisor, and interact with the medical community to determine current and future business opportunities to address unmet clinical needs.
“Medtronic is privileged to welcome such a renowned physician to our business, and we look forward to Dr. Sharan’s many contributions in his new role as we look to further build upon our strong innovation and evidence strategy and expand access to our underserved patient populations,” Nnamdi Njoku, president of Medtronic’s Neuromodulation business, told the press.
Dr. Sharan is one of the top neurosurgeons in the U.S. with 25 years of experience. He is currently co-director of the Neuro Restoration Center and Professor of Neurological Surgery and Neurology at Thomas Jefferson University, Jefferson Medical College, and previously held roles of President for both the Congress of Neurological Surgeons and the North American Neuromodulation Society.
Dr. Sharan will shape the company’s strategic direction of innovation and clinical evidence plans, guide physician, society, and education engagements, serve as the business’s medical advisor, and interact with the medical community to determine current and future business opportunities to address unmet clinical needs.
“Medtronic is privileged to welcome such a renowned physician to our business, and we look forward to Dr. Sharan’s many contributions in his new role as we look to further build upon our strong innovation and evidence strategy and expand access to our underserved patient populations,” Nnamdi Njoku, president of Medtronic’s Neuromodulation business, told the press.